EA201000895A1 - Композиции и способы для лечения лизосомных болезней - Google Patents

Композиции и способы для лечения лизосомных болезней

Info

Publication number
EA201000895A1
EA201000895A1 EA201000895A EA201000895A EA201000895A1 EA 201000895 A1 EA201000895 A1 EA 201000895A1 EA 201000895 A EA201000895 A EA 201000895A EA 201000895 A EA201000895 A EA 201000895A EA 201000895 A1 EA201000895 A1 EA 201000895A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
diseases
compositions
lizosome
treatment
Prior art date
Application number
EA201000895A
Other languages
English (en)
Inventor
Клиффорд А. Лингвуд
Майкл С. Макгрэт
Арастех Ари Азхир
Original Assignee
Де Хоспитал Фо Сик Чилдрен
Ньюралтус Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Де Хоспитал Фо Сик Чилдрен, Ньюралтус Фармасьютикалс, Инк. filed Critical Де Хоспитал Фо Сик Чилдрен
Publication of EA201000895A1 publication Critical patent/EA201000895A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

В настоящем изобретении предложены композиции и способы для лечения лизосомных болезней с использованием класса производных и соединений замещенного имидазола.
EA201000895A 2007-11-29 2008-11-26 Композиции и способы для лечения лизосомных болезней EA201000895A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99113607P 2007-11-29 2007-11-29
US9582508P 2008-09-10 2008-09-10
PCT/US2008/085039 WO2009073564A1 (en) 2007-11-29 2008-11-26 Compositions and methods for treating lysosomal disorders

Publications (1)

Publication Number Publication Date
EA201000895A1 true EA201000895A1 (ru) 2010-12-30

Family

ID=40718117

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000895A EA201000895A1 (ru) 2007-11-29 2008-11-26 Композиции и способы для лечения лизосомных болезней

Country Status (10)

Country Link
US (3) US8252789B2 (ru)
EP (1) EP2211856A4 (ru)
JP (2) JP2011505374A (ru)
AU (1) AU2008334094B2 (ru)
BR (1) BRPI0822349A2 (ru)
CA (1) CA2706727A1 (ru)
EA (1) EA201000895A1 (ru)
GB (1) GB2466912B (ru)
IL (1) IL205939A (ru)
WO (1) WO2009073564A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073564A1 (en) 2007-11-29 2009-06-11 The Hospital For Sick Children Compositions and methods for treating lysosomal disorders
CA2728363C (en) 2008-06-26 2019-02-19 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
AU2011335545A1 (en) 2010-11-30 2013-06-13 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
PT2685986T (pt) 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
EP2970269B1 (en) 2013-03-14 2017-04-19 Novartis AG 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases
EP3089963A1 (en) 2013-10-30 2016-11-09 Novartis AG 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof
PT3193840T (pt) 2014-09-15 2021-08-10 Orphazyme Aps Formulação de arimoclomol
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
KR102254140B1 (ko) 2016-04-29 2021-05-24 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP4005638A4 (en) * 2019-07-29 2023-07-05 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
AU2021311131A1 (en) 2020-07-24 2023-03-23 Genzyme Corporation Pharmaceutical compositions comprising venglustat
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
DE3916072A1 (de) 1989-05-17 1990-11-22 Thera Ges Fuer Patente Ceramidderivate und ihre verwendung als inhibitoren der sphingolipidsynthese
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5700826A (en) 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
JP2002522509A (ja) 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
US20020147197A1 (en) 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
US20030095953A1 (en) 1999-11-12 2003-05-22 Myles C. Cabot Methods of reversing drug resistance in cancer cells
AU2001236713A1 (en) 2000-02-17 2001-08-27 Genzyme Corporation Methods for treatment of lysosomal storage diseases
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
BR0206400A (pt) 2001-01-10 2005-01-18 Univ Michigan Compostos de amino ceramidas e seus usos em métodos terapêuticos
JP3692492B2 (ja) 2001-05-01 2005-09-07 独立行政法人科学技術振興機構 新規なスフィンゴ脂質合成阻害剤
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
WO2003011879A1 (en) 2001-08-01 2003-02-13 Neose Technologies, Inc. Neutral glycosphingolipids and glycosyl-sphingosines and methods for isolating the same
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
CN101899006B (zh) * 2002-08-19 2013-11-06 劳洛斯治疗公司 2，4，5-三取代的咪唑及其作为抗菌剂的用途
AU2004262494B2 (en) * 2003-07-29 2009-01-15 Universitaetsklinikum Muenster Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
WO2007064091A1 (en) 2005-12-02 2007-06-07 Seoul National University Industry Foundation Pharmaceutical composition comprising p38 map kinase inhibitor for treating diseases caused by npc1 gene deficiency or self-renewal disorder of stem cells
US8163791B2 (en) 2007-02-26 2012-04-24 Industry-Academic Cooperation Foundation, Yonsei University Imidazole derivatives that induce apoptosis and their therapeutic uses
WO2009073564A1 (en) 2007-11-29 2009-06-11 The Hospital For Sick Children Compositions and methods for treating lysosomal disorders
BRPI0920498A2 (pt) * 2008-11-14 2019-09-24 Neuraltus Pharmaceuticals Inc método de tratamento de uma condição em um sujeito

Also Published As

Publication number Publication date
JP2014224139A (ja) 2014-12-04
IL205939A (en) 2014-07-31
US20090163500A1 (en) 2009-06-25
US20150202185A1 (en) 2015-07-23
WO2009073564A1 (en) 2009-06-11
EP2211856A4 (en) 2011-02-09
BRPI0822349A2 (pt) 2019-09-24
GB2466912A (en) 2010-07-14
AU2008334094B2 (en) 2015-01-22
CA2706727A1 (en) 2009-06-11
US8252789B2 (en) 2012-08-28
GB2466912B (en) 2012-01-04
JP2011505374A (ja) 2011-02-24
GB201008522D0 (en) 2010-07-07
EP2211856A1 (en) 2010-08-04
IL205939A0 (en) 2010-11-30
AU2008334094A1 (en) 2009-06-11
US9023845B2 (en) 2015-05-05
US20130012539A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
EA201170521A1 (ru) Новые соединения
EA201070247A1 (ru) Ингибиторы протеасом
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
EA201170832A1 (ru) Пуриновые соединения
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
EA200900798A1 (ru) Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
EA200802213A1 (ru) Способы лечения заболеваний крови
EA200700225A1 (ru) Аналоги тетрапептида
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA200870569A1 (ru) Соединения и способы модуляции fxr
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EA201170834A1 (ru) Соединения, пригодные для ингибирования chk1
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren